Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept versus epoetin alfa in ESA-naive lower-risk MDS with transfusion-dependent anemia
jRCT2080224135Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial in myelodysplastic syndrome (MDS) and anaemia comparing Luspatercept with Epoetin alfa (2 arms). Started Nov 2018; status: completed.
02
Drugs
luspaterceptepoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)anaemia
Beyond the preview
Go deeper on jRCT2080224135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224135.